Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of “Hold” from Brokerages

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $10.8333.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th.

Hedge Funds Weigh In On Cardiff Oncology

Several institutional investors have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC boosted its position in shares of Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after acquiring an additional 553,317 shares during the last quarter. Laurion Capital Management LP lifted its position in Cardiff Oncology by 37.2% during the third quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after purchasing an additional 668,590 shares during the last quarter. Raymond James Financial Inc. grew its stake in shares of Cardiff Oncology by 70.1% in the 3rd quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock worth $49,000 after buying an additional 9,740 shares in the last quarter. Brooklyn Investment Group bought a new stake in shares of Cardiff Oncology in the 3rd quarter worth about $26,000. Finally, AlphaCore Capital LLC raised its position in shares of Cardiff Oncology by 8.2% during the 3rd quarter. AlphaCore Capital LLC now owns 109,926 shares of the company’s stock valued at $226,000 after buying an additional 8,351 shares in the last quarter. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Down 0.4%

CRDF stock opened at $2.40 on Wednesday. The stock has a market cap of $161.66 million, a P/E ratio of -3.04 and a beta of 1.35. Cardiff Oncology has a twelve month low of $1.90 and a twelve month high of $5.64. The business’s 50-day moving average price is $2.24 and its 200-day moving average price is $2.67.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. On average, equities research analysts expect that Cardiff Oncology will post -0.99 earnings per share for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.